Advancing Toward a World Without Vision Loss From Diabetes: Insights From The Mary Tyler Moore Vision Initiative Symposium 2024 on Curing Vision Loss From Diabetes DOI Creative Commons

Ward Fickweiler,

Konstantina Sampani, Dorene S. Markel

et al.

Translational Vision Science & Technology, Journal Year: 2025, Volume and Issue: 14(5), P. 12 - 12

Published: May 8, 2025

The Mary Tyler Moore Vision Initiative (MTM Vision) honors Moore's commitment to ending vision loss from diabetes. Founded by husband, Dr. S. Robert Levine, MTM aims accelerate breakthroughs in diabetic retinal disease (DRD). At the Symposium 2024 on Curing Loss Diabetes, experts highlighted urgent need for updated DRD staging systems, clinically relevant endpoints, and novel biomarkers detect early changes. is advancing two clinical trials collaboration with DRCR Retina Network, launching a public awareness campaign, welcoming Boehringer Ingelheim as first founding industry member of its pre-competitive Consortium. Speakers emphasized big-data strategies artificial intelligence (AI)-driven tools improve diagnosis, risk prediction, personalized treatment. They also showcased new efforts bridge academic discoveries expertise, illustrating promising work vascular regeneration cellular senescence that may yield future therapies. Biorepository Resource Center expanding tissue collections, enabling multi-omics analyses study mechanisms. Patient voices were central discussion, calls enhanced patient-reported outcomes, caregiver support, broader education DRD's risks. symposium underscored importance integrating mental health, quality life measures, ongoing patient input guide research.

Language: Английский

A systems view of the vascular endothelium in health and disease DOI Creative Commons
Hellmut G. Augustin, Gou Young Koh

Cell, Journal Year: 2024, Volume and Issue: 187(18), P. 4833 - 4858

Published: Sept. 1, 2024

Language: Английский

Citations

30
Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial DOI
Joshua N. Farr, Elizabeth J. Atkinson,

Sara J. Achenbach

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(9), P. 2605 - 2612

Published: July 2, 2024

Language: Английский

Citations

18
Therapeutic targeting of senescent cells in the CNS DOI
Markus Rießland, Methodios Ximerakis, Andrew A. Jarjour

et al.

Nature Reviews Drug Discovery, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 30, 2024

Language: Английский

Citations

12
Enhancing immunity during ageing by targeting interactions within the tissue environment DOI
Olivia V. Bracken, Roel P. H. De Maeyer, Arne N. Akbar

et al.

Nature Reviews Drug Discovery, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Language: Английский

Citations

1
Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema DOI

Sharon Klier,

J. Dananberg,

Lauren Masaki

et al.

NEJM Evidence, Journal Year: 2025, Volume and Issue: 4(5)

Published: April 22, 2025

We tested the ability of a single intravitreal injection foselutoclax (hereafter UBX1325), novel senolytic small molecule inhibitor antiapoptotic protein B-cell lymphoma-extra large, to mitigate impact diabetic macular edema. Patients with edema prior suboptimal response anti-vascular endothelial growth factor treatment were randomly assigned (1:1) either 10 μg UBX1325 or sham and followed for up 48 weeks. The primary trial objective was evaluate safety side-effect profile as assessed by ocular systemic treatment-emergent adverse events (TEAEs). Our secondary probe efficacy, defined mean changes from baseline versus in best corrected visual acuity measured Early Treatment Diabetic Retinopathy Study (ETDRS) letters (range, 0-100 letters, higher scores indicate better vision) retinal structure. Between June 2021 April 2022, 65 participants (32.3% women) (n=32) (n=33). There four TEAEs Grade 3 greater group, which three considered serious, while there five group serious. no apparent between-group differences respect vital signs, electrocardiograms, routine blood chemistries. For outcome difference between change week 5.6 more ETDRS (95% confidence interval, -1.5 12.7). In this sham-controlled that led discontinuation compared sham. trends suggestive potential efficacy; larger trials are needed further these findings. (Funded UNITY Biotechnology; ClinicalTrials.gov number, NCT04857996.).

Language: Английский

Citations

1
Resilience to diabetic retinopathy DOI Creative Commons
Anara Serikbaeva, Yanliang Li,

Simón Ma

et al.

Progress in Retinal and Eye Research, Journal Year: 2024, Volume and Issue: 101, P. 101271 - 101271

Published: May 11, 2024

Chronic elevation of blood glucose at first causes relatively minor changes to the neural and vascular components retina. As duration hyperglycemia persists, nature extent damage increases becomes readily detectable. While this second, overt manifestation diabetic retinopathy (DR) has been studied extensively, what prevents maximal from very start remains largely unexplored. Recent studies indicate that diabetes (DM) engages mitochondria-based defense during retinopathy-resistant phase, thereby enables retina remain healthy in face hyperglycemia. Such resilience is transient, its deterioration results progressive accumulation retinal damage. The concepts co-emerge with these discoveries set stage for novel intellectual therapeutic opportunities within DR field. Identification biomarkers mediators protection DM-mediated will enable development resilience-based therapies indefinitely delay onset DR.

Language: Английский

Citations

8
Mesenchymal stem cells-derived exosomes alleviate senescence of retinal pigment epithelial cells by activating PI3K/AKT-Nrf2 signaling pathway in early diabetic retinopathy DOI Creative Commons

Lifang Bai,

Ying Wang

Experimental Cell Research, Journal Year: 2024, Volume and Issue: 441(2), P. 114170 - 114170

Published: July 15, 2024

Diabetic retinopathy (DR) is a major cause of vision loss and blindness in adults. Cellular senescence was involved the pathogenesis early-stage DR positively correlated with progression. Thus, our study aimed at exploring effect potential mechanism Mesenchymal stem cells-derived exosomes (MSCs-EXOs) on Retinal Pigment Epithelial (RPE) cells an early stage vivo vitro. ARPE-19 were incubated high glucose (HG) medium mixed MSCs-EXOs to observe changes cell viability. Senescence-associated β-galactosidase (SA-β-gal) staining, Western blot qRT-PCR used assess expression senescence-related genes antioxidant mediators. Quantitative Real-Time polymerase chain reaction (qRT-PCR), Optical coherence tomography (OCT) Hematoxylin eosin (HE) staining Electroretinogram (ERG) respectively verify cellular senescence, structure function retina. Our findings demonstrated that inhibited HG-induced cells. Furthermore, reduced apoptosis oxidative stress levels while promoting proliferation. Mechanistically, HG suppressed PI3K/AKT phosphorylation as well nuclear factor erythroid 2-related 2 (Nrf2) along its downstream target gene However, reversed these by alleviating enhancing activity. In line results vitro, significantly ameliorated hyperglycemia-induced mice downregulating mRNA P53, P21, P16, SASP. Additionally, improved functional structural integrity retina mice. revealed protective offering new insights for treatment DR.

Language: Английский

Citations

7
Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights DOI Creative Commons
Ahmed Sermed Al Sakini, Abdulrahman Khaldoon Hamid,

Zainab A. Alkhuzaie

et al.

International Journal of Retina and Vitreous, Journal Year: 2024, Volume and Issue: 10(1)

Published: Oct. 28, 2024

Abstract One of the most common health concerns disturbing people within working years globally is diabetes mellitus (DM). well-known consequence DM vascular damage, which can manifest as macro- and microangiopathy affecting ocular retina. Therefore, Diabetic macular edema (DME) a major sight-threatening complication diabetic retinopathy (DR) worldwide. It prevalent cause significant vision impairment in patients. Long-term loss be avoided by following early DME treatment guidelines everyday life. Hence, there are various therapeutic approaches for management. Currently, first-line anti-VEGF family drugs, such ranibizumab, brolucizumab, bevacizumab, aflibercept. Nevertheless, relapses disease, inadequate response, resistance during therapy still seen because intricate pathophysiological foundation disease. Consequently, an excellent requirement to advance become better at controlling diseases more satisfactorily require fewer treatments overall. We conducted thorough literature search current review present comprehensive overview primary data about agents. also covered novel advances management probable future being investigated developed. This recommended that Large clinical trials should afford sufficient evidence support these innovative modalities.

Language: Английский

Citations

5
Long COVID as a Disease of Accelerated Biological Aging: An Opportunity to Translate Geroscience Interventions DOI
Areez Shafqat, Mary Clare Masters, Utkarsh Tripathi

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 99, P. 102400 - 102400

Published: June 28, 2024

Language: Английский

Citations

4
Senescent endothelial cells: a potential target for diabetic retinopathy DOI Creative Commons

Ying-Lu Liao,

Yifan Fang,

Jiaxing Sun

et al.

Angiogenesis, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 31, 2024

Diabetic retinopathy (DR) is a diabetic complication that results in visual impairment and relevant retinal diseases. Current therapeutic strategies on DR primarily focus antiangiogenic therapies, which particularly target vascular endothelial growth factor its related signaling transduction. However, these therapies still have limitations due to the intricate pathogenesis of DR. Emerging studies shown premature senescence cells (ECs) hyperglycemic environment involved disease process plays multiple roles at different stages. Moreover, surprising discoveries driven development senotherapeutics targeting senescent (SECs), present challenging but promising prospects treatment. In this review, we inducers mechanisms EC summarize current research advances SECs for Herein, highlight role played by key factors stages senescence, will be critical facilitating future innovative treatment

Language: Английский

Citations

4